Key Highlights
- BioMarin Pharmaceutical will acquire Alesta Therapeutics for $275 million upfront, with up to an additional $215 million tied to development milestones.
- The deal gives BioMarin access to ALE1, an early-stage oral treatment candidate for hypophosphatasia, a rare genetic bone disease.
- More than 9,000 people in the US have been diagnosed with hypophosphatasia, though the true prevalence is believed to be higher.
- The Acquisition marks BioMarin's third major rare disease deal in the past year, following its $4.8 billion acquisition of Amicus Therapeutics announced in December.
BioMarin Expands Rare Disease Pipeline With Alesta Deal
BioMarin Pharmaceutical (NASDAQ:BMRN) announced it will acquire Alesta Therapeutics for $275 million upfront, with up to an additional $215 million contingent on development milestones. The deal provides BioMarin access to ALE1, an oral treatment candidate currently in early-stage Clinical Trials for hypophosphatasia, a rare genetic bone disease. If successful, the drug could become the first oral treatment option available for the condition.
More than 9,000 people in the United States have been diagnosed with hypophosphatasia, according to the companies, though the true number affected is believed to be higher due to underdiagnosis. The acquisition is expected to close this quarter.
Deal Strengthens BioMarin's Rare Skeletal Conditions Portfolio
The acquisition bolsters BioMarin's existing unit focused on rare skeletal conditions, a portfolio anchored by its drug Voxzogo. It marks the company's third significant rare disease transaction over the past year, following its $4.8 billion acquisition of Amicus Therapeutics announced in December. BioMarin's CEO said the deal represents "exactly the kind of opportunity to address a significant unmet need" that allows the company to compete in larger rare disease markets, adding that BioMarin plans to continue pursuing similar opportunities as part of its focus on clinical-stage innovation.
Alesta Leadership Cites BioMarin's Scale as Key Factor
Alesta's chief executive said BioMarin's global reach and development expertise were central to the board's decision to approve the transaction, describing BioMarin as "an ideal partner to advance ALE1 and realize its potential as a promising treatment for patients with HPP worldwide." The deal continues a broader trend of larger pharmaceutical companies acquiring early-stage rare disease Assets to expand specialized treatment portfolios.






Please wait processing your request...